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Abstract We present a high throughput shotgun mass
spectrometry workﬂow using a bidimensional peptide
fractionation procedure consisting of isoelectric focusing
and RP-HPLC prior to mass spectrometric analysis, with
the aim of optimizing peptide separation and protein
identiﬁcation. As part of the workﬂow we used the
‘Isotope-Coded Protein Labeling’ (ICPL) method for accu-
rate relative quantitation of protein expression. Such work-
ﬂow was successfully applied to a comparative proteome
analysisofschizophreniaversushealthycontrolbraintissues
and can be an alternative to proteome researches.
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Abbreviation List
2-DE Two-dimensional gel electrophoresis
ACN Acetonitrile
ATL Anterior temporal lobe
DLPFC Dorsolateral prefrontal cortex
HPLC High performance liquid chromatography
ICAT Isotope-Coded Afﬁnity Tags
ICPL Isotope-Coded Protein Labeling
IEF Isoelectric focusing
IPG Immobilized pH gradient
iTRAQ Isobaric Tags for Relative and Absolute
Quantiﬁcation
MALDI Matrix-Assisted Laser Desorption/
Ionization
MS/MS Tandem mass spectrometry
MS Mass spectrometry
MW Molecular weight
pI Isoelectric point
RP-HPLC Reverse phase—high performance liquid
chromatography
SCZ Schizophrenia
Shotgun-MS Shotgun mass spectrometry
TFA Triﬂuoroacetic acid
TOF Time of ﬂight
Proteomics studies of cells and organisms grow continu-
ously at exponential rates. A number of different approa-
ches and methods have been described to achieve
comprehensive proteome analysis [8]. Although two-
dimensional gel electrophoresis (2-DE) is still used in
many proteome studies, the use of shotgun mass spec-
trometry (shotgun-MS), introduced by Link et al. [5], in
combination with stable isotope labeling methods has
received increased popularity in recent years. Shotgun-MS
in combination with chromatographic separation methods
can overcome some of the 2-DE limitations such as the bias
towards the most expressed proteins, the identiﬁcation of
proteins with extreme MWs and pIs [3] as well as low
abundant proteins such as transcription factors and mem-
brane receptors, which often play important roles disease-
associated mechanisms [17, 18].
A shotgun-MS approach basically consists in the sepa-
ration of peptides resulting from protein digestion followed
by tandem mass spectrometry (MS/MS) analysis. Compu-
tational algorithms allow the automatic assignment of
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dicted fragment spectra contained in the protein sequence
databases [4]. Stable isotope labeling methods such as
‘Isotope-Coded Afﬁnity Tags’ (ICAT) [2], ‘Isobaric Tags
for Relative and Absolute Quantiﬁcation’ (iTRAQ) [14]
and ‘Isotope-Coded Protein Labeling’ (ICPL) [15] can be
used in combination with shotgun-MS in order to compare
the proteomes of interest.
Here we present an example of a shotgun-MS workﬂow
for proteome analysis by bidimensional peptide separation
consisting of isoelectric focusing (IEF) and nano-reverse
phase liquid chromatography (RP-HPLC) followed by
tandem MALDI mass spectrometry (MALDI-TOF/TOF)
for peptide sequencing and protein identiﬁcation. This
proteomic platform is suited for the integration of a stable
isotope labeling method, such as ICPL, for relative quan-
titative proteome analysis. We have successfully used this
workﬂow for the proteome analysis of schizophrenia (SCZ)
and control human brains (Fig. 1).
Brain proteins were extracted as described [6]. Follow-
ing the ICPL kit protocol (Serva Electrophoresis, Heidel-
berg, Germany), a total of 100 lg protein from SCZ or
control samples were reduced by adding dithiothreitol
reagent and the resultant free thiol groups were alkylated
with 0.4 M iodoacetamide. Excess of iodoacetamide was
quenched by adding 0.5 M N-acetylcysteine. For protein
labeling a ten-fold molar excess of light and heavy
Nic-NHS reagent tags for control and SCZ samples,
respectively, were added and incubated for 2 h at RT.
Hydroxylamine (1.5 M) was added to the sample to inac-
tivate the remaining Nic-NHS reagents. Equal amounts of
light and heavy labeled samples were then combined. The
combined protein samples were subsequently digested with
trypsin at a 1:50 ratio (protein/enzyme) in 200 mM
NH4HCO3 (pH 8.3) at 37 C for 4 h. The resultant peptides
were fractionated by IEF on immobilized pH gradient strip
(IPG strip, 17 cm, 3.5–4.5 range). The strip was rehydrated
for 12 h and focusing was performed for 8 h at 10,000 V
constant voltage. The strip was manually cut in 47 pieces
and the peptides extracted with 1% formic acid. Each
extracted peptide sample was further fractionated on a nano
RP-C18 monolithic column (200 um id. 9 5 cm, Dionex,
Sunnyvale, CA) at a ﬂow rate of 4 lL/min using a 40 min
gradient from 10 to 100% of solvent B (ACN; 0.1% TFA)
on a micro-LC-System (HP1100 Agilent Technologies,
Waldbronn, Germany). The eluted peptides were collected
onto Prespotted AnchorChip sample target (Bruker Dal-
tonics, Bremen, Germany) using a PROTEINEER-FC
robot (Bruker Daltonics).
Mass spectra were acquired fully automatically using an
Ultraﬂex I MALDI-TOF/TOF mass spectrometer (Bruker
Daltonics) equipped with a nitrogen laser. Measurements
were performed in positive reﬂector mode and a 20,000 V
acceleration voltage. WARP-LC 1.1 software (Bruker
Daltonics) was used for the spectra acquisition and the
automatic selection of peptide signals for the subsequent
MS/MS analysis. The ICPL-labeled peptides were auto-
matically selected for the MS/MS analysis independently
of their Heavy/Light (H/L) ratio. Acquired MS and MS/MS
spectra were sent by the WARP-LC 1.1 to Biotools soft-
ware 3.1 (Bruker Daltonics) as combined peak lists and
searched against the NCBI database using an in-house
version of MASCOT 2.1 (Matrix Science, London, UK)
with the following parameter settings: Homo sapiens as
organism, trypsin as enzyme, carbamidomethylation as
ﬁxed modiﬁcation, oxidized methionine and heavy and
light ICPL labeling of lysine residue and N-terminal pro-
tein as variable modiﬁcations. The determination of ICPL-
labeled peptide pair (heavy and light) ratios was performed
by WARP-LC 1.1 Protein Browser (Bruker Daltonics), by
comparing the relative heavy and light cluster signal
intensities. The technical parameters and the instrument
settings for peptide separation and MS measurements
reported here are sample- and instrument-dependent.
The described shotgun-MS workﬂow in combination
with the ICPL labeling method was applied to the proteome
analysis of anterior temporal lobe (ATL) and dorsolateral
prefrontal cortex (DLPFC) brain regions from SCZ and
Fig. 1 Shotgun-MS workﬂow for the comparison of human SCZ and
control brain samples. The SCZ and control proteins are modiﬁed by
heavy and light ICPL reagents, respectively, mixed in equal amounts
and then digested with trypsin. The tryptic peptides are separated by
IEF and RP-HPLC and then analyzed by mass spectrometry. The
mass spectrometry peptide signal intensities enable protein identiﬁ-
cation and relative quantitation
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123control patients [9, 10]. In the ATL proteome analysis, 837
peptides were identiﬁed, leading to the identiﬁcation of 479
proteins, 37 of which were differentially expressed accord-
ing the statistical analysis (t-test) performed by WARP-LC
1.1, considering the signal intensities and number of iden-
tiﬁed peptides per protein. In the DLPFC proteome analysis,
we identiﬁed 2,541 peptides which led to the identiﬁcation
of 1,261 proteins, 84 of which were differentially expressed,
using the same statistical analysis described above. In both
comparative proteome analyses, ‘‘one-hit wonder’’ proteins
were not considered as identiﬁed (Fig. 2). The proteins we
found to be differentially expressed between SCZ and
controls not only revealed new interesting data but also
conﬁrmed previous transcriptome and proteome results
obtained by other groups [1, 12, 13, 16].
The combination of IEF and RP-HPLC for tryptic
peptide fractionationpriortoMSprovidesapowerfultoolfor
proteome proﬁling and biomarker discovery. The presented
ICPL shotgun-MS method has enabled the identiﬁcation of
regulated and non-regulated proteins in the same experiment
while in 2-DE comparative analyses usually only the differ-
entially expressed proteins are selected and identiﬁed.
Using shotgun-MS [10] we were able to identify 84
differentially expressed proteins statistically signiﬁcant (as
described above) in DLPFC between SCZ patients and
controls. These proteins are involved in 11 biological
processes. Using 2-DE comparative analysis of the same
brain region, the volumes of all protein spots in SCZ and
controlsgelsweredeterminedandcorrespondingspotswere
matched for all 2-DE proﬁles. Next, the spot volumes were
analyzed by t-test, revealing 24 statistically signiﬁcant dif-
ferences in the protein expression, involved in 6 biological
processes [11]. These results conﬁrm the notion that shot-
gun-MS is more efﬁcient in the higher detection differen-
tially expressed proteins as well as in the identiﬁcation of
low abundant proteins, which may play important roles in
brain diseases [7]. Whereas only 2 out of 24 (8.3%) differ-
entially regulated proteins found by 2-DE were membrane
proteins, with shotgun-MS 190 (15.1%) of the expressed
proteins were identiﬁed as membrane proteins, even though
we did not apply membrane protein enrichment protocols.
Yet, by 2-DE, 8.3% were extracellular proteins, and the
remaining 83.4% were cytoplasmatic proteins, while by
shotgun-MS, not only extracellular proteins were identiﬁed,
but also nuclear (15.3%) and vesicular proteins (6.8%) were
revealed. Furthermore, it is known that the determination of
quantitative protein expression differences using stable
isotope methods is more accurate than the determination by
densitometric measurements of 2-DE spots [4, 8].
Analyzing our shotgun-MS data, we have observed an
issue concerning the number of identiﬁed peptides per pro-
tein. In the DLPFC and ATL data analysis, 65% and 49% of
proteins, respectively, were identiﬁed by only 2 peptides
(Fig. 2). This is probably due to the use of the ICPL meth-
odology. Since the ICPL tag modiﬁes lysine residues in the
intact proteins, the subsequent trypsin digestion occurs only
at arginine residues generating long peptides whose frag-
mentation by MS/MS is incomplete. As a consequence a
lower number of peptides is identiﬁed compared to tryptic
digests where cleavage occurs at both lysine and arginine
residues. A solution to this issue could be the use of the
selected stable isotope labeling method at peptide level.
For the proteome analysis of SCZ thalamus, we have
integrated in our shotgun-MS workﬂow the iTRAQ technol-
ogy, which labels the lysine residues and the N-termini of the
proteolytic peptides. As a result, we observed an increased
number of identiﬁed peptides per protein and an increased
number of identiﬁed proteins (data to be published).
The presented shotgun-MS workﬂow can overcome the
issue of the high proteome complexity by using multidi-
mensional separation with IEF and RP-HPLC for tryptic
peptides fractionation. The combination of the orthogonal
and multidimensional separation methods reduces peptide
complexity to a level that allows a successful MS analysis.
Moreover, the techniques used in this workﬂow are auto-
mated and enable high-throughput experiments. Further-
more, the shotgun-MS workﬂow described here is
compatible with the use of stable isotope reagents.
Although the search for the best method for representing
proteomes is still on-going, we have presented here a
Number of identified peptides per protein in DLPFC
2 peptides
65%
More than 3 
peptides
25%
3 peptides
10%
Number of identified peptides per protein in ATL
3 peptides
27%
2 peptides
49%
More than 3 
peptides
24%
A 
B 
Fig. 2 Number of identiﬁed peptides per protein obtained using our
shotgun-MS workﬂow for the analysis of ATL (A) and in DLPFC (B)
brain tissue samples from SCZ patients and controls
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123shotgun-MS workﬂow that can be applied to any kind
of proteome as an alternative and/or complement to the
2-DE-based proteome analysis.
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